Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

NCT00031915 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Childhood Malignant Fibrous Histiocytoma of Bone
Sarcoma

Interventions

DRUG: imatinib mesylate

Sponsor

National Cancer Institute (NCI)